Other agents, such as tricin or urolithin A, have also shown positive impacts on diabetic retinopathy [207,208], highlighting Nrf2 as a promising therapeutic target in the management of diabetic retinopathy. The gene discussed is NFE2L2; the disease is diabetic retinopathy.